{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T05:59:48Z","timestamp":1780898388399,"version":"3.54.1"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Inclisiran is a subcutaneously administered synthetic small interfering RNA directed against proprotein convertase subtilisin\u2013kexin type 9, leading to sustained low-density lipoprotein cholesterol (LDL-C) reduction with a twice-yearly dosing regimen. While its lipid-lowering efficacy is well established, its broader metabolic effects remain incompletely characterized. This study aimed to comprehensively evaluate serum metabolomic and lipoproteomic changes in patients with dyslipidemia before and after inclisiran treatment using an integrated nuclear magnetic resonance (NMR)-based approach.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This observational single-center study included 69 patients with dyslipidemia treated with inclisiran in routine clinical practice. Fasting serum samples were collected at baseline and 3\u00a0months after treatment initiation. A total of 30 metabolites and 112 lipoprotein-related parameters were quantified using NMR spectroscopy. Paired comparisons between time points were performed using the Wilcoxon signed-rank test with false discovery rate correction. Clustering based on lipoprotein changes was conducted using the KODAMA algorithm to identify distinct response patterns.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Inclisiran treatment was associated with extensive and coherent reductions in lipoprotein-related parameters. Seventy-four lipoprotein variables showed significant changes. Reductions were observed across LDL, IDL, and VLDL subclasses, while some HDL-related parameters were increased. In contrast, the global metabolomic profile remained largely unchanged; trimethylamine-N-oxide (TMAO) was the only metabolite significantly increased at follow-up. KODAMA clustering identified three patient groups with heterogeneous responses. Two groups demonstrated marked lipoprotein reductions, particularly those with higher baseline LDL-related parameters, whereas one group exhibited minimal changes. Baseline TMAO levels were lower in the group with the most pronounced lipid response and increased at follow-up, potentially reflecting changes in concomitant lipid-lowering therapy rather than a direct effect of inclisiran.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Inclisiran induces a broad and consistent improvement in lipoprotein profiles, extending beyond LDL-C reduction, with minimal impact on the overall metabolome. These findings support the highly specific lipid-lowering action of inclisiran and highlight inter-individual variability in treatment response, especially in concomitant lipid-lowering therapies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1824522","type":"journal-article","created":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T05:33:56Z","timestamp":1780896836000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Effects of inclisiran therapy on metabolomic and lipoproteomic profiles in dyslipidemic patients"],"prefix":"10.3389","volume":"17","author":[{"given":"Jacopo","family":"Patrussi","sequence":"first","affiliation":[{"name":"Department of Chemistry \u201cUgo Schiff\u201d, University of Florence","place":["Florence, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Vignoli","sequence":"additional","affiliation":[{"name":"Department of Chemistry \u201cUgo Schiff\u201d, University of Florence","place":["Florence, Italy"]},{"name":"Magnetic Resonance Center (CERM), University of Florence","place":["Florence, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"Tenori","sequence":"additional","affiliation":[{"name":"Department of Chemistry \u201cUgo Schiff\u201d, University of Florence","place":["Florence, Italy"]},{"name":"Magnetic Resonance Center (CERM), University of Florence","place":["Florence, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Sorrentino","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Medicine, University of Florence","place":["Florence, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Berteotti","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Medicine, University of Florence","place":["Florence, Italy"]},{"name":"Azienda Ospedaliero-Universitaria Careggi","place":["Florence, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Lotti","sequence":"additional","affiliation":[{"name":"Azienda Ospedaliero-Universitaria Careggi","place":["Florence, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felice","family":"Crudele","sequence":"additional","affiliation":[{"name":"Azienda Ospedaliero-Universitaria Careggi","place":["Florence, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Ciarrocca Taranta","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Medicine, University of Florence","place":["Florence, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela Antonietta","family":"Rogolino","sequence":"additional","affiliation":[{"name":"Azienda Ospedaliero-Universitaria Careggi","place":["Florence, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Barbieri","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Medicine, University of Florence","place":["Florence, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Maria","family":"Gori","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Medicine, University of Florence","place":["Florence, Italy"]},{"name":"Azienda Ospedaliero-Universitaria Careggi","place":["Florence, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossella","family":"Marcucci","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Medicine, University of Florence","place":["Florence, Italy"]},{"name":"Azienda Ospedaliero-Universitaria Careggi","place":["Florence, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"5117","DOI":"10.1073\/pnas.1220873111","article-title":"Knowledge discovery by accuracy maximization","volume":"111","author":"Cacciatore","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B2","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1056\/NEJMoa1609243","article-title":"A highly durable RNAi therapeutic inhibitor of PCSK9","volume":"376","author":"Fitzgerald","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.cmet.2008.04.001","article-title":"The cholesterol absorption inhibitor ezetimibe acts by blocking the sterol-induced internalization of NPC1L1","volume":"7","author":"Ge","year":"2008","journal-title":"Cell Metab."},{"key":"B4","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.pnmrs.2023.10.002","article-title":"Fingerprinting and profiling in metabolomics of biosamples","author":"Ghini","year":"2023","journal-title":"Prog. Nucl. Magnetic Reson. Spectrosc."},{"key":"B5","doi-asserted-by":"publisher","first-page":"194","DOI":"10.3390\/metabo12020194","article-title":"The potential of metabolomics in biomedical applications","volume":"12","author":"Gonzalez-Covarrubias","year":"2022","journal-title":"Metabolites"},{"key":"B6","doi-asserted-by":"publisher","first-page":"11962","DOI":"10.1021\/acs.analchem.8b02412","article-title":"Quantitative lipoprotein subclass and low molecular weight metabolite analysis in human serum and plasma by 1H NMR spectroscopy in a multilaboratory trial","volume":"90","author":"Jim\u00e9nez","year":"2018","journal-title":"Anal. Chem."},{"key":"B7","doi-asserted-by":"publisher","first-page":"301","DOI":"10.17179\/excli2020-3239","article-title":"Trimethylamine N-oxide (TMAO) in human health","volume":"20","author":"Ka\u0142u\u017cna-Czapli\u0144ska","year":"2021","journal-title":"EXCLI J."},{"key":"B8","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1056\/NEJMp1614154","article-title":"Oligonucleotide therapeutics - a new class of cholesterol-lowering drugs","volume":"376","author":"Khvorova","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1093\/ajcn\/nqac074","article-title":"Gut microbiota\u2013derived metabolite trimethylamine-N-oxide and multiple health outcomes: an umbrella review and updated meta-analysis","volume":"116","author":"Li","year":"2022","journal-title":"Am. J. Clin. Nutr."},{"key":"B10","doi-asserted-by":"publisher","first-page":"3363","DOI":"10.2147\/DDDT.S512207","article-title":"Decoding TMAO in the gut-organ axis: from biomarkers and cell death mechanisms to therapeutic Horizons","volume":"19","author":"Liu","year":"2025","journal-title":"DDDT"},{"key":"B11","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur. Heart J."},{"key":"B12","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/S2213-8587(22)00353-9","article-title":"Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial","volume":"11","author":"Ray","year":"2023","journal-title":"Lancet Diabetes and Endocrinol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"e158183","DOI":"10.1172\/jci.insight.158183","article-title":"Aorta- and liver-generated TMAO enhances trained immunity for increased inflammation via ER stress\/mitochondrial ROS\/Glycolysis pathways","volume":"8","author":"Saaoud","year":"2023","journal-title":"JCI Insight"},{"key":"B14","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1021\/acs.jproteome.9b00345","article-title":"NMR-based metabolomics for the assessment of inhaled pharmacotherapy in chronic obstructive pulmonary disease patients","volume":"19","author":"Vignoli","year":"2020","journal-title":"J. Proteome Res."},{"key":"B15","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/164_2022_618","article-title":"NMR-based metabolomics to evaluate individual response to treatments","volume":"277","author":"Vignoli","year":"2022","journal-title":"Handb. Exp. Pharmacol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"e157","DOI":"10.1097\/FJC.0000000000001053","article-title":"Inclisiran: a novel agent for lowering apolipoprotein B\u2013containing lipoproteins","volume":"78","author":"Warden","year":"2021","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/nrd.2016.32","article-title":"Emerging applications of metabolomics in drug discovery and precision medicine","volume":"15","author":"Wishart","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1093\/cvr\/cvae109","article-title":"Inclisiran administration potently and durably lowers LDL-C over an extended-term follow-up: the ORION-8 trial","volume":"120","author":"Wright","year":"2024","journal-title":"Cardiovasc. Res."},{"key":"B19","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s12944-022-01673-3","article-title":"The associations between TMAO-Related metabolites and blood lipids and the potential impact of rosuvastatin therapy","volume":"21","author":"Xiong","year":"2022","journal-title":"Lipids Health Dis."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1070394","DOI":"10.3389\/fmolb.2022.1070394","article-title":"KODAMA exploratory analysis in metabolic phenotyping","volume":"9","author":"Zinga","year":"2022","journal-title":"Front. Mol. Biosci."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1824522\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T05:33:57Z","timestamp":1780896837000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1824522\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,8]]},"references-count":20,"alternative-id":["10.3389\/fphar.2026.1824522"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1824522","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,8]]},"article-number":"1824522"}}